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Tbjective: Aprotinin, a serine protease inhibitor, decreases transfusion requirements
nd inflammatory response after cardiopulmonary bypass. This study was done to
etermine whether aprotinin is associated with adverse outcomes, particularly
ortality and acute kidney failure, in pediatric patients (18 years of age) under-
oing cardiopulmonary bypass.
ethods: We compared a cohort of all pediatric cardiopulmonary bypass operations
rom 1994–1999, when aprotinin was not used (n  1230), with a cohort from
000–2006, when all patients received high-dose aprotinin (n 1251). Primary end
oints were operative and late mortality, acute kidney failure, need for dialysis, and
eurologic complications. Association of aprotinin with primary end points was
ssessed by means of univariate analysis, multivariate logistic regression, and Cox
egression analysis, where appropriate.
esults: The aprotinin group was younger (mean age, 3.49  1.84 vs 3.64  4.75
ears; P .019) and had a higher Aristotle score (7.8 2.3 vs 7.2 2.6, P .001).
nivariate and multivariate analysis showed no significant difference between the
o-aprotinin and aprotinin groups for operative mortality (55 [4.5%] vs 47 [3.8%],
 .508), acute kidney failure (68 [6.0%] vs 69 [5.7%], P  .77), need for
emporary dialysis (6 [0.49%] vs 12 [0.96%], P .17), or neurologic complications
14 [1.1%] vs 17 [1.4%], P  .62). By means of Cox regression analysis, aprotinin
ad no influence on late mortality (24 vs 10 deaths, P  .078).
onclusion: In this retrospective cohort study of pediatric patients undergoing
ardiopulmonary bypass, there was no association between the use of aprotinin and
cute kidney failure, need for dialysis, neurologic complications, and operative or
ate mortality. We continue to use aprotinin for all pediatric patients undergoing
ardiopulmonary bypass.
protinin (Trasylol; Bayer Pharmaceutical, West Haven, Conn) is an antifi-
brinolytic serine protease inhibitor purified from bovine lung. Aprotinin
was approved by the US Food and Drug Administration to reduce periop-
rative blood loss in high-risk patients undergoing cardiopulmonary bypass (CPB)
or coronary artery bypass grafting in 1993.1 Aprotinin reduces bleeding by delayin
he rapid plasmin-mediated lysis of the fibrin clot. Several randomized, prospective,
lacebo-controlled, carefully performed trials on aprotinin use have shown that it
educes requirements for blood transfusion in adult cardiac surgery.2-4 Aprotinin has
lso been shown to decrease the inflammatory response to CPB.5,6 After completing
n internal study that demonstrated that aprotinin reduced operative closure time and
lood product use after pediatric cardiac bypass, our center began routinely using
protinin in all of our patients undergoing CPB in early 2000.7 Several other
ediatric cardiac surgery centers have shown that the use of aprotinin in pediatric
he Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 6 1421
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Datients undergoing CPB is associated with decreased use of
lood products and cost savings from decreased operative
ime.8,9
Recently, the safety of aprotinin use in adult cardiac
urgery has been called into question, particularly in 2
eparate reports published by Mangano and colleagues.10,11
hey reported that aprotinin use was associated with in-
reased risk of perioperative acute kidney failure, cerebral
ascular accidents, and long-term mortality. Both studies
ave elicited numerous letters to the editor and
ditorials.12-14
The purpose of our study was to determine whether the
se of aprotinin was associated with adverse outcomes,
articularly mortality and impairment of kidney function, in
ediatric patients (18 years of age) undergoing CPB. We
lso analyzed the patients with regard to postoperative new-
nset neurologic injury. The conduct of this study was
acilitated by our change in treatment protocols to in-
lude aprotinin in all of our patients undergoing CPB in
arly 2000. This study was not directed at the efficacy of
protinin; it was limited to the safety issues recently
aised.
aterials and Methods
his was a retrospective, nonrandomized cohort study. The Insti-
utional Review Board at Children’s Memorial Hospital, Chicago,
llinois, approved this study and granted a waiver of informed
onsent on May 4, 2006. We identified patients through the com-
uterized database for cardiac surgical patients at Children’s Me-
orial Hospital, which was established in 1990. We compared all
ediatric patients having CPB for the 6-year period before use of
protinin (1994–1999) with a cohort of patients who all received
protinin (2000–2006). The aprotinin protocol that we used is
hown in Table 1. The primary outcome measures evaluated 
perative and late mortality, biochemical acute kidney failure, and
he need for temporary dialysis. Operative mortality was defined as
eath within 30 days of an operation or within the primary hospi-
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
DHCA deep hypothermic circulatory arrest
ABLE 1. Aprotinin protocol at Children’s Memorial
ospital
● 1-mL test dose after arterial line placed
● 171.5 mL/m2 patient loading and pump prime dose (maximum,
200 mL)
● 40 mL/m2/h infusion through bypass run and for 1 h
postoperatively (maximum, 50 mL/h).
● 1 mL  10,000 KIU
422 The Journal of Thoracic and Cardiovascular Surgery ● Decalization (Society of Thoracic Surgeons and European Associa-
ion for Cardiothoracic Surgery definition).15 Biochemical acute
idney failure was defined as an increase in serum creatinine levels
o twice or more than the preoperative level (personal e-mail
ommunication with J. P. Jacobs, Multi-Societal Pediatric and
ongenital Cardiac Database Taskforce, 2007). The serum creat-
nine value selected for analysis was the peak value in the first
ostoperative 72 hours.16 The need for temporary dialysis w
efined as any patient having placement of an intravenous dialysis
atheter or peritoneal dialysis catheter that was used for dialysis at
ny time during the hospital stay.
Demographic and clinical characteristics were summarized by
sing means and standard deviations for continuous variables and
requencies for categorical variables and compared between the 2
tudy groups by using t tests and 2 tests. All outcomes of interest
ere as follows: biochemical acute kidney failure, postoperative
emporary dialysis, operative mortality, and late mortality are
inary. In addition to aprotinin, predictors studied included age,
ex, body surface area, operative status (emergency status vs
onemergency status), Aristotle score, deep hypothermic circula-
ory arrest (DHCA; yes vs no), preoperative ventilator support (yes
s no), prior open cardiothoracic operations (yes vs no), CPB time,
ortic crossclamp time, and preoperative serum creatinine level.
he data consisted of multiple operations per patient over the study
eriod. The repeated nature of the data was taken into consider-
tion in the regression analyses.
A Cox regression frailty model (Therneau) with a random
ffect for patient was used to determine predictors of late mortal-
ty.17 Time at risk was defined by using the Anderson–Gill-
roach. Time at risk for patients with multiple operations was from
ne surgical date to the next. Follow-up times were censored at
pril 27, 2007. A generalized linear model for binary outcome
Liang and Zeger) with logit link was used to determine predictors
f the other 3 outcomes. Repeated measures were modeled by
sing compound symmetry structure.18 The overall strategy was 
se results from univariate associations as a data reduction tool to
dentify candidates for a multiple-predictor model. Univariate
odels included each predictor one at a time, controlling for
protinin. A P value of .1 determined inclusion in a multiple-
redictor model in addition to predictors that were statistically
ignificantly different between the 2 study groups. In addition, the
nteraction effect between aprotinin and risk stratification based on
he median Aristotle score was explored. Separate models for each
evel were considered if this effect was statistically significant.
ower considerations allowed for multiple-predictor models for
iochemical acute kidney failure and operative mortality out-
omes. Odds ratios and corresponding 95% confidence intervals
re presented for statistically significant categorical predictors. The
ncidence of neurologic outcomes was low, and hence the 2 test
as used to test the association between aprotinin and outcome if
dverse outcomes were observed in at least 10 operations. The low
ncidence did not allow for repeated-measures analyses of multiple
perations.
Statistical analyses were conducted with SAS statistical soft-
are (version 9.1; SAS, Cary, NC) and S-Plus (version 6.2;
nsightful Corp, Seattle, Wash). All conclusions were made at the
05 level of significance.
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Desults
he demographic and operative predictors of the 2 patient
ohorts are shown in Table 2. The patients who rec
protinin were younger than the patients who did not re-
eive aprotinin. The aprotinin group contained more pa-
ients having an operation with emergency status. The Ar-
stotle score of the patients who received aprotinin was
igher than that of the patients who did not receive aproti-
in. There was no significant difference between the groups
n body surface area, CPB time, crossclamp time, use of
irculatory arrest, preoperative serum creatinine level, prior
pen cardiothoracic operations, and preoperative ventilator
upport.
perative Mortality
he mortality for the no-aprotinin group was 4.5%, and in
he aprotinin group it was 3.8% (P  .37, Table 3). Con
rolling for other patient risk factors in the multivariate
nalysis, there continued to be no association between apro-
inin and operative mortality (P  .508, Table 4). Signifi
ant predictors of operative mortality in this model were use
f DHCA, preoperative ventilator support, longer CPB
ime, and smaller body surface area.
iochemical Acute Kidney Failure
n the no-aprotinin group biochemical acute kidney failure
ABLE 2. Patient population: Demographics and operative
redictors
No
aprotinin Aprotinin P value
emographics
No. of patients 1083 1007
No. of operations 1230 1251 —
Age (y) 3.64 4.75 3.49 1.84 .019*
BSA 0.57  0.41 0.54 0.45 .084
Male sex 52.5% 55.4% .4
perative predictors
Aristotle score 7.23 2.57 7.81 2.31 .001*
Emergency status 49 87 .011*
Prior open CT
operations
338 362 .42
Preoperative
ventilator support
202 211 .77
Preoperative serum
creatinine level
(mg/dL)
0.49 0.26 0.52 0.39 .07
DHCA 107 86 .09
CPB time (min) 124 67 120 65 .067
Aortic crossclamp
time (min)
58.9 45.2 59.3 45.7 .82
SA, Body surface area; CT, cardiothoracic; DHCA, deep hypothermic
irculatory arrest; CPB, cardiopulmonary bypass. *Significant.ccurred in 68 (6.0%) of 1133 patients. In the aprotinin c
The Journal of Thoracicroup this occurred in 69 (5.7%) of 1210 patients (P .76).
ata were incomplete regarding serum creatinine levels for
38 (6.6%) patients, 97 in the no-aprotinin group and 41 in
he aprotinin group. Controlling for other patient risk factors
n the multivariate analysis, there was no association be-
ween aprotinin and biochemical acute kidney failure (P 
77, Table 5). Significant predictors of biochemical a
idney failure in this model were use of DHCA, preopera-
ive ventilator support, younger age, longer CPB time, and
ower preoperative creatinine level.
A subanalysis was done in which patients were stratified
nto low- or high-risk groups by using the median Aristotle
core (7.8) as the cutoff value. The interaction effect be-
ween aprotinin and risk category was not statistically sig-
ificant (P  .5), indicating that aprotinin did not have a
ifferential effect on the outcome of biochemical acute
idney failure, depending on risk status.
emporary Dialysis
n the no-aprotinin group 6 (0.49%) of 1229 patients re-
uired temporary dialysis in the postoperative period. In the
protinin group this was 12 (0.96%) of 1251 (P  .166).
emporary dialysis was associated with a 61% mortality
ABLE 3. Results: Univariate analysis
No
aprotinin Aprotinin P value
perative mortality 55 47 .37
iochemical acute kidney failure 68 69 .76
ean highest postoperative
serum creatinine (mg/dL)
0.58 0.31 0.6 0.33 .08
emporary dialysis 6 12 .166
ortality caused by dialysis 5 6 .99
ABLE 4. Operative mortality: Multivariate analysis
redictor P value Odds ratio
95% Confidence
interval
protinin .51 — —
mergency status .079 — —
HCA .001* 3.32 1.8-6.0
reoperative
ventilator support
.001* 3.61 1.9-6.9
redictor P value
No
operative
mortality
Operative
mortality
ge (y) .29 3.5 4.8 0.8 2.5
SA .008* 0.57 0.43 0.28 0.22
ristotle score .68 7.4 2.4 9.7 3.3
PB time (min) .001* 120 57 175 102
HCA, Deep hypothermic circulatory arrest; BSA, body surface area; CPB,
ardiopulmonary bypass. *Significant.
and Cardiovascular Surgery ● Volume 134, Number 6 1423
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Date because 11 of these 18 patients died. It should be noted
hat all of these were very complex procedures; no patient
ho had a straightforward cardiac procedure had postoper-
tive acute kidney failure. The mean Aristotle score of the
o-aprotinin group to require dialysis was 7.7, and the mean
core in the aprotinin group requiring dialysis was 10.1.
ortality related to temporary dialysis was similar in both
roups. There were 5 (0.41%) deaths in dialyzed patients in
he no-aprotinin group and 6 (0.48%) deaths in dialyzed
atients in the aprotinin group (P  .99). There was no
ower for multivariable models beyond the 2 predictor models.
dds ratios for predictors are from the univariate model. Pre-
ictors of temporary dialysis were emergency status, use of
HCA, preoperative ventilator support, higher Aristotle score,
onger CPB time, and higher preoperative serum creatinine
evel (Table 6). No patient required permanent dialysis.
eurologic Outcomes
ur cardiac surgery database includes a category for neu-
ologic complications, one of which is “postoperative new-
nset neurologic deficit persisting at discharge.” In the
o-aprotinin group this occurred in 3 (0.24%) of 1230
atients, and in the aprotinin group this occurred in 3
0.24%) of 1251 patients. In the no-aprotinin group postop-
rative new-onset seizures occurred in 11 (0.89%) of 1230
atients. In the aprotinin group these occurred in 14 (1.1%)
f 1251 patients (P  .58). There was no statistically
ignificant difference observed between the 2 groups for
ither neurologic outcome.
dverse Reactions and Re-exposures
wo patients had a possible anaphylactic reaction to apro-
ABLE 5. Biochemical acute kidney failure: Multivariate
nalysis
redictor P value Odds ratio
95% Confidence
interval
protinin .77 — —
HCA .001* 3.05 1.68–5.53
reoperative
entilator support
.003* 2.27 1.33–3.88
redictor P value
No acute kidney
failure
Acute
kidney
failure
ge (y) .017* 3.5 4.8 2.0 3.9
ristotle score .063 7.5 2.4 8.5 2.7
PB time (min) .001* 119 58 153 73
reoperative serum
creatinine level
(mg/dL)
.001* 0.51 0.3 0.39 0.2
HCA, Deep hypothermic circulatory arrest; CPB, cardiopulmonary bypass.
Significant.inin. In both cases it was their first exposure to the drug, y
424 The Journal of Thoracic and Cardiovascular Surgery ● Decnd neither patient had a reaction to the initial test dose. The
rst patient became hypotensive on aprotinin administra-
ion, with a decrease in systolic blood pressure from 110 to
0 mm Hg. Systolic blood pressure recovered to baseline
fter discontinuation of aprotinin and with administration of
opamine and fluids. The second patient had decreased lung
ompliance after aprotinin administration, necessitating dis-
ontinuation of aprotinin. The patient recovered to baseline
ulmonary function after administration of epinephrine bo-
uses and dopamine.
There were 91 patients who were re-exposed to aprotinin
nce within 1 year of their first exposure. Three additional
atients were re-exposed more than once within a year of
heir exposure to aprotinin. No adverse events were associ-
ted with re-exposure to aprotinin in this series.
ate Mortality
s determined by means of Cox regression analysis, apro-
inin had no influence on late mortality (24 deaths in the
o-aprotinin group vs 10 deaths in the aprotinin group, P 
078). This analysis was of course complicated by the sep-
rate time cohorts, with significantly more follow-up in the
o-aprotinin group. However, this was counterbalanced by
he relatively short mean time to late mortality in all groups.
he mean time to late death in all groups was 1.7  2.3
ears (median, 0.77 years). In the no-aprotinin group mean
ime to late death was 2.23  2.49 years (median, 1.3
ears), and in the aprotinin group mean time to late death
as 0.44  6.5 years (median, 0.22 years). The mean
ollow-up time in the no-aprotinin group was 8.54  3.79
ABLE 6. Postoperative temporary dialysis: Univariate
nalysis
redictor P value Odds ratio
95% Confidence
interval
protinin .166 — —
mergency status .001* 6.3 2.2–17.9
HCA .001* 6.4 2.3–17.6
reoperative
ventilator support
.001* 5.1 2.0–13.0
redictor P value
No
temporary
dialysis
Temporary
dialysis
ge (y) .09 — —
ristotle score .001* 7.5  2.5 9.3  2.6
PB time (min) .001* 121  60 196  114
reoperative serum
creatinine level
(mg/dL)
.031* 0.5  0.3 0.9  0.7
HCA, Deep hypothermic circulatory arrest; CPB, cardiopulmonary bypass.
Significant.ears (median, 9.4 years), and in the aprotinin group the
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Dean follow-up was 3.47  1.99 years (median, 3.3 years).
ean and median follow-up times in the aprotinin group
ncompass the mean and median times to late mortality.
able 7 shows the predictors of late mortality. These
luded preoperative ventilator support, preoperative emer-
ency status, prior open cardiothoracic operation, higher
ristotle score, and longer CPB time.
imitations
he primary limitation of this study was that the patients
ere not randomly assigned and were not contemporane-
us. There might have been changes in the operative and
ostoperative protocols that affected the outcomes irrespec-
ive of aprotinin administration, thus creating an uninten-
ional time-based selection bias in our study. However, a
ery important factor is that there was no selection bias for
he use or nonuse of aprotinin. There was a distinct policy
hange in early 2000, and all patients undergoing CPB
eceived aprotinin after that time. The bias between the 2
ohorts, which would actually factor against aprotinin for
oorer outcomes in this group, are that the patients in the
protinin group were slightly younger (3.49 vs 3.64 years)
nd had a significantly higher Aristotle score (7.81 vs 7.23).
he Aristotle score has been validated as an indicator of
ostoperative mortality.19 In addition, there were mo
mergency cases in the aprotinin group (87 vs 49).
The analyses of aprotinin risk in relation to postoperative
eurologic deficit and seizure are based on complication
ncidence, as recorded in our comprehensive cardiac surgery
atabase. We found no statistically significant difference
etween the 2 groups for either outcome. However, these
atients did not have routine postoperative examinations by
neurologist or routine postoperative neurologic imaging,
nd therefore this analysis is not comprehensive. Manifes-
ations of neurologic injury can be subtle and might only
ABLE 7. Late mortality: Cox regression analysis (time to
vent outcome)
redictor P value
Odds
ratio
95% Confidence
interval
protinin .78 — —
reoperative
ventilatory support
.001* 4 2–8.1
mergency status .001* 6.65 2.6–16.9
rior open CT
operations
.043* 2 1–4
redictor P value
No late
mortality
Late
mortality
ristotle Score .001* 7.4  2.4 8.6 2.0
PB time (min) .001* 119  57 149 62
T, Cardiothoracic; CPB, cardiopulmonary bypass. *Significant.ecome evident over time. w
The Journal of Thoracic-
iscussion
his retrospective study of 2090 patients operated on be-
ween 1994 and 2006 was performed to assess the safety of
protinin in pediatric patients undergoing CPB. This study
as facilitated by a policy change to use aprotinin in all
atients undergoing CPB in early 2000. The two 6-year
ohorts of patients were compared.
The impetus for this study was the recent article, “The
isk associated with aprotinin in cardiac surgery,” by Man-
ano and associates.10 This was a propensity-adjusted o-
ervational study that reported that aprotinin use (n 1295)
as associated with a doubling of the risk of perioperative
cute kidney failure and cerebral vascular accidents in pa-
ients undergoing CPB grafting. This study has elicited
umerous letters to the editor and editorials and has called
nto question the use of aprotinin for patients undergoing
PB.12,14 Another report from Mangano and associate11
orrelated the use of aprotinin (n  1072) with a signifi-
antly increased late mortality in patients undergoing coro-
ary artery bypass graft surgery. This report was also the
ubject of an editorial response. 14 The primary question
aised regarding the Mangano studies are related to the
eason the patients receive the drug therapy (aprotinin) in
he first place and the influence of that selection bias on the
atient data collection process and analysis and patient out-
omes.12-14 Our review would indicate that for pediatric -
ients, the use of aprotinin (n 1251) was not associated with
n increase in the risk of biochemical acute kidney failure,
eed for dialysis, or neurologic complications and also was not
ssociated with increased risk of operative or late mortality.
his was despite the fact that the aprotinin group of patients
as statistically younger and had a higher Aristotle score.
One counterintuitive finding was that the preoperative
erum creatinine level in the patients who had biochemical
cute kidney failure was less preoperatively than the level in
hose patients who did not have biochemical acute kidney
ailure. The answer to why the lower serum creatinine value
as a predictor of postoperative acute kidney failure is
robably explained by the fact that younger children tended
o have kidney failure (2.0 vs 3.5 years). The younger cohort
f children has a lower muscle mass and therefore a lower
erum creatinine level as normal baseline. Our definition of
iochemical acute kidney failure as an increase in serum
reatinine level to twice or more than the preoperative level
ses each patient’s preoperative serum creatinine level as
is or her own control, a practice that is consistent with our
Children’s Memorial Hospital) internal standard for the
efinition of acute kidney failure, as well as that of our
ardiac surgery database (personal e-mail communication
ith J. P. Jacobs, Multi-Societal Pediatric and Congenital
ardiac Database Taskforce, 2007). In addition, it should be
oted that although the preoperative serum creatinine values
ere lower in those children who had acute kidney failure,
and Cardiovascular Surgery ● Volume 134, Number 6 1425
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Dhe respective values of 0.39 versus 0.51 mg/dL, although
tatistically different, are not clinically different.
It should be clearly noted that our study was not performed
o demonstrate the efficacy of aprotinin in pediatric patients.
here have been numerous previous studies to indicate that
protinin is indeed efficacious in pediatric patients undergoing
PB. A recent meta-analysis by Arnold and colleagues20 re-
orted that aprotinin reduced the proportion of children who
eceived red blood cell or whole blood transfusions during
ardiac surgery by 33%. Our own study published in 2003
emonstrated that with the use of aprotinin, children were
xposed to 3 instead of 5 red blood cell units. Operative closure
ime was less (ie, 93 vs 127 minutes, a savings of 34 minutes).
he Ann Arbor group in 1996 reported in a prospective,
andomized, placebo-controlled, double-blind trial that aproti-
in resulted in fewer exposures to bank-blood components and
as also associated with a savings in the patient charges for
lood components, operating room time, and duration of hos-
italization.8 The group from Eggleston Children’s Hospital
998 reported similar findings.9
A recent study at the University of California, San Fran-
isco, evaluated the use or nonuse of aprotinin in patients
ndergoing the Norwood, Glenn, and Fontan procedures.
he authors concluded the following: “The key point of
hese data is that we did not see evidence of clinical concern
n this population of children with . . . aprotinin. If anything
ur data support the safety of these drugs for use in children
ndergoing the repair of congenital cardiac defects.”21 The
ilwaukee group, in particular, has demonstrated the utility
nd safety of aprotinin use and reuse in pediatric patients
ndergoing cardiothoracic procedures.22,23 They concluded
hat the risk of hypersensitivity reactions to aprotinin is low
approximately 1%), even with multiple exposures to the
edication. Our analysis of the risk of re-exposure confirms
he Milwaukee analysis; we had no adverse responses in 94
atients re-exposed within 1 year.
In our study of 2090 pediatric patients undergoing CPB,
here was no association between the use of high-dose aproti-
in and operative or late mortality, biochemical acute kidney
ailure, need for temporary dialysis, or neurologic complica-
ions. Given the previous studies demonstrating its efficacy, we
ontinue to use aprotinin in all pediatric patients undergoing
PB.
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r James S. Tweddell (Milwaukee, Wis). That was an excellent
resentation, Carl, as usual. This is a timely contribution from the
roup at Children’s Memorial Hospital. The authors looked at their
ntire experience with aprotinin, a period of 6 years, and compared
his with the previous 6-year period. Just over 2000 patients are
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Dncluded, pretty much evenly divided between the use and nonuse
f aprotinin, making this the largest single-center report concern-
ng aprotinin use in pediatrics by far.
Despite an increase in case complexity in the most recent
protinin cohort, there is no difference in mortality or renal im-
airment, suggesting that aprotinin use is safe in this age group.
ncidentally, our aprotinin use policy is identical to yours.
The limitations of this study have been acknowledged by the
uthors and most importantly include the comparison of noncon-
emporary patient groups. I would contend that this is a form of
election bias.
This study begins in 1994, and just for some perspective, in
994, the sitcom “Friends” premiered on NBC, Netscape 1.0 was
eleased, and George Bush was unequivocally elected governor of
exas. Times have changed.
Since 1994, we have seen some important changes in various
spects of preoperative, intraoperative, and postoperative manage-
ent of patients with congential heart disease, including some
ioneered from your institution.
Taking the devil’s advocate position, one could argue that your
ost recent results, which are excellent, would have been even
etter if you had not used aprotinin. Therefore my comments and
uestions are really directed at potential ways around this time–
ias issue.
The most recent studies from the Ischemia Research and Edu-
ation Foundation purported to show that aprotinin use was asso-
iated with a significantly increased risk of complications in
dults—myocardial infarction, stroke and renal failure—in pa-
ients not having complex operations. Could you or did you
nalyze the effect of aprotinin risk within risk stratification cate-
ories? You could divide your patient population above and below
he 50th percentile Aristotle score, for example, and this would be
way to match aprotinin use and risk stratification. Perhaps the
isk/benefit ratio of aprotinin is favorable for high-risk patients but
ot so for low-risk patients. You had these data, and I think this
ould make an additional excellent analysis, and I would like to
ear your comments on that.
Dr Backer. We did try to look at risk stratification based on
ristotle scores. We were particularly interested in the group of
atients who required postoperative temporary dialysis because
hose were the patients who clearly had substantial kidney failure.
he mean Aristotle score in the no-aprotinin group that required
ialysis was 7.67. All of these patients had difficult operations,
uch as tricuspid valve replacement after heart transplantation and
isrupted aortic annulus with emergency operation.
The mean Aristotle score in the aprotinin group that required
ialysis was 10.08, a high score that was almost statistically higher
han that of the other group. If you look at this patient population,
gain, all these patients were at very high risk. There was a Fontan
onversion with an Aristotle score of 12, there were 2 patients in
eart transplantation status after Fontan conversion, there was a
ransplantation after a ventricular assist device, and there was a
atient with a switch with an intramural coronary artery who was
n extracorporeal membrane oxygenation. We did not have any
atient who had, for example, a straightforward ventricular septal
efect closure and then had kidney failure.
The other part of the data to look at is the multivariate analysis
f biochemical acute kidney failure. The mean Aristotle score in s
The Journal of Thoraciche group without acute kidney failure was 7.5, and in those with
cute kidney failure, it was 8.5. The Aristotle score only trended to
ignificance, with a P value of .063. In the patients who required
ostoperative temporary dialysis, where the Aristotle score was
tatistically significant (P  .001), it was 7.5 in the patients who
id not require dialysis and 9.3 in the patients who did require
ostoperative dialysis.
However, your point is well taken, and we could incorporate
isk stratification as a specific subanalysis of the data.
Dr Tweddell. Those are certainly compelling data, but I would
uggest that it might be worthwhile performing the analysis.
Concerning the incidence of renal insufficiency, as determined
ased on chemical data, interestingly, the preoperative creatinine
evel was less in patients who sustained postoperative biochemical
enal dysfunction, at least the way you defined it. This really
auses me to question the validity of this definition. I know you
sed the somewhat arbitrary definition that was developed by the
ociety of Thoracic Surgeons in the multidisciplinary working
roup, and the purpose of that is really to allow some multi—
nstitutional comparisons. Because this is a single-institution study
nd because I am certain Children’s Memorial has age—specific
reatinine ranges of normalcy, you could actually analyze that
eparately. I think that would be important because that is obvi-
usly an important conclusion of your article.
Dr Backer. That is a good point. We discussed with our
ediatric nephrologists what definition we should use for acute
idney failure. One of the problems with taking the absolute value
s that if a sick patient’s preoperative creatinine level is increased,
or instance to 1.5 times normal value, then a postoperative level
f 1.5 times normal value is not a change. The Society of Thoracic
urgeons–European Association for Cardiothoracic Surgery defi-
ition of acute kidney failure is a doubling of the creatinine level
ompared with the preoperative value or a level that is 1.5 times
ormal value, but the doubling seemed to take precedence for this
eason. Our pediatric nephrologists believed that using doubling of
he preoperative creatinine level as our definition would “widen
he net,” so that we would not miss patients with borderline
ostoperative kidney failure.
You noted, as we did in the article, that in the multivariate
nalysis there was the counterintuitive finding that the preoperative
reatinine level was 0.51 mg/dL in the patients who did not have
cute kidney failure, and it was 0.39 mg/dL in the patients who did
ave acute kidney failure. The question here is whether a creati-
ine level of 0.5 versus 0.4 mg/dL is actually clinically relevant.
In contrast, for those patients who required postoperative tem-
orary dialysis, the association of preoperative creatinine level was
ignificant, with a P value of .03. The patients who did not require
emporary dialysis had a mean preoperative creatinine level of 0.5
g/dL. If they did require temporary dialysis, the mean preoper-
tive value was 0.9 mg/dL. Therefore in the subgroup with kidney
ailure requiring postoperative dialysis, they did have a higher
reoperative creatinine level, almost twice as high as before the
peration.
Dr Tweddell. I guess I was suggesting that you use the most
nclusive definition because that is important to rule it out. Also, I
hink that is more important than the application of dialysis be-
ause that is really measuring a clinical response and not neces-
arily biochemical evidence of renal failure.
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DI have just a couple of other questions. Aprotinin is a strong
nhibitor of bradykinin generation. Bradykinin is implicated in
erioperative neurologic injury. Did you look at neurologic com-
lications, seizures, and new deficits?
Dr Backer. We do have neurologic data in our database,
lthough we did not specifically look at it. We could go back and
nalyze that relatively easily. However, we do not currently have
ate follow-up on neurologic outcomes.
Dr Tweddell. Have you had incidents of anaphylaxis, and how
o you re-expose? Do you re-expose patients within a year?
Dr Backer. We relied on your article in Circulation that
uggested that it was safe to redose aprotinin. The main group
ndergoing re-exposure within a year consisted of those who had
he Norwood procedure with aprotinin and then within 4 to 6
onths had the bidirectional Glenn procedure. Initially, our anes-
hesiologists were hesitant to use aprotinin during the Glenn pro-
edure. Your article came out with the less than 1% anaphylaxis,
nd therefore currently, we administer aprotinin at the Norwood
nd Glenn procedures, irrespective of whether they have their
lenn procedure at 3.5, 4, or 6 months, and again at the Fontan
rocedure.
Our primary safety protocol is that every patient gets a test dose
f aprotinin, and we wait to do that until the arterial line and the
entral line are in. We have had one patient who had significant
ypotension related to the aprotinin—just one patient out of this
ntire group.
Dr Tweddell. Obviously there are no indications for aprotinin
se in pediatrics, but there is now a black box warning about
e-exposure within a year.Dr Backer. Yes. p
428 The Journal of Thoracic and Cardiovascular Surgery ● DecDr Tweddell. It is one thing to use it when there is not an
ndication, and it is another thing to use it against a black box
arning. I wonder if you have changed your policy at all? I think
e are struggling with that as well.
Dr Backer. We have not changed our policy. The Friday
efore I came here, I did a reoperation to do a shunt revision on a
atient after the Norwood procedure. We had used aprotinin 10
ays earlier, and I used aprotinin again, and nothing happened.
ranted, it is only 1 patient.
Dr Tweddell. My last and final question is whether you think
e need a postmarket randomized controlled trial in pediatrics to
pprove efficacy and safety?
Dr Backer. Well, I think in an ideal world that would be a good
hing. I think if there are enough questions about this and if centers
re unable to use aprotinin because of the negative press and
ecause of parental concerns, a randomized prospective study
ight be the only way we are going to prove its safety. There have
een several studies that have showed efficacy, and we could look
t efficacy and safety in the prospective trial. Specifically, we
ould look at kidney function and even do some more in-depth
nalysis, such as postoperative GFR and postoperative urine col-
ections for creatinine clearance.
Dr Tweddell. Thank you. Excellent article.
Dr Kenneth G. Warner (Boston, Mass). Did you see any
ncreased incidence of thrombotic complications in the aprotinin
roup, such as strokes, premature closure of fenestrations, and
eep vein thrombosis?
Dr Backer. No. I mean, we have almost no thrombosis in our
atients and that was not—we did not see that.
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